CHDI
Listed here are over 1,075 publications that describe some of the research funded (in whole or in part) by CHDI Foundation. You can also view just the subset of publications that have CHDI staff as authors.
Publication Search
Title
Journal
Oakeshott S, Farrar A, Port R, Cummins-Sutphen J, Berger J, Watson-Johnson J, Ramboz S, Howland D, Brunner D
Deficits in a simple visual go/no-go discrimination task in two mouse models of Huntington`s Disease
Kudwa AE, Menalled LB, Oakeshott S, Murphy C, Mushlin R, Fitzpatrick J, Miller SF, McConnell K, Port R, Torello J, Howland D, Ramboz S, Brunner D
Increased body weight of the BAC HD transgenic mouse model of Huntington`s Disease accounts for some but not all of the observed HD-like motor deficits
Balci F, Oakeshott S, Shamy JL, El-Khodor BF, Filippov I, Mushlin R, Port R, Connor D, Paintdakhi A, Menalled L, Ramboz S, Howland D, Kwak S, Brunner D
High-throughput automated phenotyping of two genetic mouse models of Huntington`s Disease
Gray MA, Egan GF, Ando A, Churchyard A, Chua P, Stout JC, Georgiou-Karistianis N
Prefrontal activity in Huntington`s disease reflects cognitive and neuropsychiatric disturbances: the IMAGE-HD study
Sawiak SJ, Wood NI, Carpenter TA, Morton AJ
Huntington's disease mouse models online: high-resolution MRI images with stereotaxic templates for computational neuroanatomy
Bouchard J, Truong J, Bouchard K, Dunkelberger D, Desrayaud S, Moussaoui S, Tabrizi SJ, Stella N, Muchowski PJ
Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease
Vlamings R, Benazzouz A, Chetrit J, Janssen ML, Kozan R, Visser-Vandewalle V, Steinbusch HW, von Hörsten S, Temel Y
Metabolic and electrophysiological changes in the basal ganglia of transgenic Huntington's disease rats
Beconi MG, Yates D, Lyons K, Matthews K, Clifton S, Mead T, Prime M, Winkler D, O`Connell C, Walter D, Toledo-Sherman L, Munoz-Sanjuan I, Dominguez C
Metabolism and pharmacokinetics of JM6 in mice: JM6 is not a prodrug for Ro-61-8048
Miller JP, Yates BE, Al-Ramahi I, Berman AE, Sanhueza M, Kim E, de Haro M, DeGiacomo F, Torcassi C, Holcomb J, Gafni J, Mooney SD, Botas J, Ellerby LM, Hughes RE
A genome-scale RNA-interference screen identifies RRAS signaling as a pathologic feature of Huntington's disease
Hadzi TC, Hendricks AE, Latourelle JC, Lunetta KL, Cupples LA, Gillis T, Mysore JS, Gusella JF, MacDonald ME, Myers RH, Vonsattel JP
Assessment of cortical and striatal involvement in 523 Huntington disease brains
Marullo M, Valenza M, Leoni V, Caccia C, Scarlatti C, De Mario A, Zuccato C, Di Donato S, Carafoli E, Cattaneo E
Pitfalls in the detection of cholesterol in Huntington's disease models
Weiss A, Trager U, Wild EJ, Grueninger S, Farmer R, Landles C, Scahill RI, Lahiri N, Haider S, Macdonald D, Frost C, Bates GP, Bilbe G, Kuhn R, Andre R, Tabrizi SJ
Mutant huntingtin fragmentation in immune cells tracks Huntington`s disease progression
J Clin Invest
October 1, 2012
122 (10) :3731-6
122 (10) :3731-6
PMID: 22996692
PMCID: PMC3461928
DOI: 10.1172/JCI64565
Reiner A, Wang HB, Del Mar N, Sakata K, Yoo W, Deng YP
BDNF may play a differential role in the protective effect of the mGluR2/3 agonist LY379268 on striatal projection neurons in R6/2 Huntington's disease mice
Prime ME, Brookfield FA, Courtney SM, Gaines S, Marston RW, Ichihara O, Li M, Vaidya D, Williams H, Pedret-Dunn A, Reed L, Schaertl S, Toledo-Sherman L, Beconi M, Macdonald D, Munoz-Sanjuan I, Dominguez C, Wityak J
Irreversible 4-Aminopiperidine Transglutaminase 2 Inhibitors for Huntington`s Disease
ACS Med Chem Lett
September 13, 2012
3 (9) :731-5
3 (9) :731-5
PMID: 24900540
PMCID: PMC4025765
DOI: 10.1021/ml3001352
Parker JA, Vazquez-Manrique RP, Tourette C, Farina F, Offner N, Mukhopadhyay A, Orfila AM, Darbois A, Menet S, Tissenbaum HA, Neri C
Integration of β-catenin, sirtuin, and FOXO signaling protects from mutant huntingtin toxicity
Smith MM, Mills JA, Epping EA, Westervelt HJ, Paulsen JS, PREDICT-HD Investigators of the Huntington Study Group
Depressive symptom severity is related to poorer cognitive performance in prodromal Huntington disease
Scahill RI, Wild EJ, Tabrizi SJ
Biomarkers for Huntington`s disease: an update
Expert Opin Med Diagn
September 1, 2012
6 (5) :371-5
6 (5) :371-5
PMID: 23480802
Wolf RC, Sambataro F, Vasic N, Wolf ND, Thomann PA, Saft C, Landwehrmeyer GB, Orth M
Default-mode network changes in preclinical Huntington`s disease
Caron NS, Munsie LN, Keillor JW, Truant R
Using FLIM-FRET to measure conformational changes of transglutaminase type 2 in live cells
Yu D, Pendergraff H, Liu J, Kordasiewicz HB, Cleveland DW, Swayze EE, Lima WF, Crooke ST, Prakash TP, Corey DR
Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression
Sontag EM, Lotz GP, Agrawal N, Tran A, Aron R, Yang G, Necula M, Lau A, Finkbeiner S, Glabe C, Marsh JL, Muchowski PJ, Thompson LM
Methylene blue modulates huntingtin aggregation intermediates and is protective in Huntington's disease models
HD iPSC Consortium
Induced pluripotent stem cells from patients with Huntington`s disease show CAG-repeat-expansion-associated phenotypes
Vlamings R, Zeef DH, Janssen ML, Oosterloo M, Schaper F, Jahanshahi A, Temel Y
Lessons learned from the transgenic Huntington's disease rats
Landles C, Weiss A, Franklin S, Howland D, Bates G
Caspase-6 does not contribute to the proteolysis of mutant huntingtin in the HdhQ150 knock-in mouse model of Huntington's disease
Shirasaki DI, Greiner ER, Al-Ramahi I, Gray M, Boontheung P, Geschwind DH, Botas J, Coppola G, Horvath S, Loo JA, Yang XW
Network organization of the huntingtin proteomic interactome in mammalian brain
Dumas EM, Versluis MJ, van den Bogaard SJ, van Osch MJ, Hart EP, van Roon-Mom WM, van Buchem MA, Webb AG, van der Grond J, Roos RA, Track-Hd investigators
Elevated brain iron is independent from atrophy in Huntington`s Disease
Stout JC, Jones R, Labuschagne I, O’Regan AM, Say MJ, Dumas EM, Queller S, Justo D, Santos RD, Coleman A, Hart EP, Dürr A, Leavitt BR, Roos RA, Langbehn DR, Tabrizi SJ, Frost C
Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease
Reiner A, Lafferty DC, Wang HB, Del Mar N, Deng YP
The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease mice
Culver BP, Savas JN, Park SK, Choi JH, Zheng S, Zeitlin SO, Yates JR 3rd, Tanese N
Proteomic analysis of wild-type and mutant huntingtin-associated proteins in mouse brains identifies unique interactions and involvement in protein synthesis
Kordasiewicz HB, Stanek LM, Wancewicz EV, Mazur C, McAlonis MM, Pytel KA, Artates JW, Weiss A, Cheng SH, Shihabuddin LS, Hung G, Bennett CF, Cleveland DW
Sustained therapeutic reversal of Huntington`s disease by transient repression of huntingtin synthesis
Harrington DL, Smith MM, Zhang Y, Carlozzi NE, Paulsen JS, PREDICT-HD Investigators of the Huntington Study Group
Cognitive domains that predict time to diagnosis in prodromal Huntington disease
Giles P, Elliston L, Higgs GV, Brooks SP, Dunnett SB, Jones L
Longitudinal analysis of gene expression and behaviour in the HdhQ150 mouse model of Huntington's disease
Brain Res Bull
June 1, 2012
88 (2-3) :199-209
88 (2-3) :199-209
PMID: 22001697
Bowles KR, Brooks SP, Dunnett SB, Jones L
Gene expression and behaviour in mouse models of HD
Long JD, Matson WR, Juhl AR, Leavitt BR, Paulsen JS, Predict-Hd Investigators, Coordinators of the Huntington Study Group
8OHdG as a marker for Huntington disease progression
Brooks SP, Janghra N, Workman VL, Bayram-Weston Z, Jones L, Dunnett SB
Longitudinal analysis of the behavioural phenotype in R6/1 (C57BL/6J) Huntington`s disease transgenic mice
Brain Res Bull
June 1, 2012
88 (43864) :94-103
88 (43864) :94-103
PMID: 21272613
Wood NI, Sawiak SJ, Buonincontri G, Niu Y, Kane AD, Carpenter TA, Giussani DA, Morton AJ
Direct evidence of progressive cardiac dysfunction in a transgenic mouse model of Huntington's disease
Gafni J, Papanikolaou T, Degiacomo F, Holcomb J, Chen S, Menalled L, Kudwa A, Fitzpatrick J, Miller S, Ramboz S, Tuunanen PI, Lehtimaki KK, Yang XW, Park L, Kwak S, Howland D, Park H, Ellerby LM
Caspase-6 activity in a BACHD mouse modulates steady-state levels of mutant huntingtin protein but is not necessary for production of a 586 amino acid proteolytic fragment
Vidal RL, Figueroa A, Court FA, Thielen P, Molina C, Wirth C, Caballero B, Kiffin R, Segura-Aguilar J, Cuervo AM, Glimcher LH, Hetz C
Targeting the UPR transcription factor XBP1 protects against Huntington's disease through the regulation of FoxO1 and autophagy
Nucifora LG, Burke KA, Feng X, Arbez N, Zhu S, Miller J, Yang G, Ratovitski T, Delannoy M, Muchowski PJ, Finkbeiner S, Legleiter J, Ross CA, Poirier MA
Identification of novel potentially toxic oligomers formed in vitro from mammalian-derived expanded huntingtin exon-1 protein
Young FB, Butland SL, Sanders SS, Sutton LM, Hayden MR
Putting proteins in their place: palmitoylation in Huntington disease and other neuropsychiatric diseases